Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

XERS stock hub

Xeris Biopharma Holdings, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

XERSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

XERS

In the news

Latest news · XERS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E45.7

P25 12.3P50 18.4P75 33.1

Trailing P/E101.9

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC8.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All XERS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001346302
Company name	Xeris Biopharma Holdings, Inc.
Country	United States
Country code	US
Cusip	98422E103
Employees	435
Employees Change	41%
Employees Change Percent	10.41
Enterprise value	$1.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-06-21
Isin	US98422E1038
Last refreshed	2026-05-10
Market cap	$1.1B
Market cap category	Small-Cap
Price	$6.53
Price currency	USD
Rev Per Employee	723,800x
Sector	Healthcare
Sic	2834
Symbol	XERS
Website	https://www.xerispharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.07%
EV Earnings	106.11x
EV Sales Forward	3.26x
EV/EBIT	35.49x
EV/EBITDA	26.5x
EV/FCF	26.81x
EV/Sales	4.05x
FCF yield	4.22%
Forward P/E	45.66x
P/B ratio	86.6x
P/E ratio	101.87x
P/S ratio	3.58x
PS Forward	2.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.4%
EBITDA Margin	15.27%
FCF margin	15.09%
Gross margin	85.89%
Gross Profit	$270.4M
Gross Profit Growth	47.81%
Gross Profit Growth Q	41.18%
Gross Profit Growth3 Y	39.47%
Gross Profit Growth5 Y	72.95%
Net Income	$12M
Net Income Growth Quarters	6%
Net Income Growth Years	4%
Pretax Margin	3.81%
Profit Margin	3.81%
Profit Per Employee	$27,605
Profitable Years	1
ROA	6.34
Roa5y	-10.92
ROCE	13.13
ROIC	8.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	45.8%
Cagr3y	39.59%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	41.48x
Revenue Growth Q	38.27x
Revenue Growth Quarters	26x
Revenue Growth Years	9x
Revenue Growth3 Y	37.4x
Revenue Growth5 Y	63.63x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.89
Assets	$392M
Cash	$111.8M
Current Assets	$251.7M
Current Liabilities	$118.6M
Debt	$258.6M
Debt EBITDA	$4.61
Debt Equity	$19.87
Debt FCF	$5.44
Equity	$13M
Interest Coverage	1.25
Liabilities	$379M
Long Term Assets	$140.3M
Long Term Liabilities	$260.4M
Net Cash	$-146.8M
Net Cash By Market Cap	$-13.02
Net Debt EBITDA	$3.05
Net Debt Equity	$11.28
Net Debt FCF	$3.09
Tangible Book Value	$-95.2M
Tangible Book Value Per Share	$-0.55
WACC	9.22

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.12
Inventory Turnover	0.7
Net Working Capital	$27.6M
Quick ratio	1.42
Working Capital	$133.1M
Working Capital Turnover	$3.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-19.55%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	45.76%
200-day SMA	7.09
3Y total return	172.08%
50-day SMA	5.91
50-day SMA vs 200-day SMA	50under200
All Time High	10.08
All Time High Change	-35.22%
All Time High Date	2025-11-05
All Time Low	0.97
All Time Low Change	573.13%
All Time Low Date	2023-01-05
ATR	0.28
Beta	0.92
Beta1y	1.39
Beta2y	1.3
Ch YTD	-16.82
High	6.64
High52	10.08
High52 Date	2025-11-05
High52ch	-35.22%
Low	6.32
Low52	4.3
Low52 Date	2025-06-13
Low52ch	51.86%
Ma50ch	10.43%
Premarket Change Percent	2.11
Premarket Price	$6.77
Premarket Volume	6,025
Price vs 200-day SMA	-7.89%
RSI	60.91
RSI Monthly	56.94
RSI Weekly	50.3
Sharpe ratio	0.87x
Sortino ratio	1.47
Total Return	-19.55%
Tr YTD	-16.82
Tr1m	11.24%
Tr1w	3.98%
Tr3m	-6.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$12.33
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.01
Earnings Revenue Estimate	79,999,336x
Earnings Revenue Estimate Growth	33.07x
Operating Income	$35.9M
Operating margin	11.4
Price target	$10.83
Price Target Change	$65.85
Price Target Change Top	$88.82

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	163,840,922%
Float Percent	94.9%
Shares Insiders	5.1%
Shares Institutions	59.63%
Shares Out	172,642,055
Shares Qo Q	-1.36%
Shares Yo Y	19.55%
Short Float	9.61%
Short Ratio	9.41
Short Shares	9.12

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$25.5M
Average Volume	1,610,385.4x
Bv Per Share	0.08
CAPEX	$-1M
Ch1m	11.24
Ch1w	3.98
Ch1y	45.76
Ch3m	-6.85
Ch3y	172.1
Ch6m	-12.11
Change	-1.51%
Change From Open	-0.61
Close	6.63
Days Gap	-0.9
Depreciation Amortization	12,178,000
Dollar Volume	19,721,873.4
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$35.9M
EBITDA	$48.1M
EPS	$0.06
F Score	7
FCF	$47.5M
FCF EV Yield	3.73x
FCF Per Share	$0.28
Financing CF	5,689,000
Fiscal Year End	December
Founded	2,005
Goodwill	22,859,000
Graham Number	0.32977
Graham Upside	-94.95
Investing CF	-1,008,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Ma150	7.05
Ma150ch	-7.35%
Ma20	6.18
Ma20ch	5.63%
Net CF	53,208,000
Next Earnings Date	2026-08-06
Open	6.57
Optionable	Yes
P FCF Ratio	23.72
P OCF Ratio	23.23
Position In Range	65.63
Post Close	6.53
Postmarket Change Percent	0.04
Postmarket Price	$6.53
Ppne	26,982,000
Pre Close	6.63
Price Date	2026-05-08
Price EBITDA	$23.45
Relative Volume	1.88x
Revenue	314,853,000x
SBC By Revenue	7.01x
Share Based Comp	22,063,000
Tr6m	-12.11%
Us State	Illinois
Volume	3,020,195
Z Score	0.79

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does XERS pay a dividend?

Capital-return profile for this ticker.

Performance

XERS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns XERS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+59.6%

Float: +94.9% of shares outstanding

Insider ownership

+5.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

XERS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

60.9

Neutral momentum band

Price vs 200-day MA

-7.9%

50/200-day relationship not available

Beta (5Y)

0.92

Moves roughly with the market

Sharpe ratio

0.87

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About XERS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current XERS stock rating?

Xeris Biopharma Holdings, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full XERS analysis?

The full report lives at /stocks/XERS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for XERS?

The latest report frames XERS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the XERS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.